| Literature DB >> 26671018 |
Florence Riché1,2, Etienne Gayat3,4,5, Romain Barthélémy6,7, Matthieu Le Dorze8,9, Joaquim Matéo10,11, Didier Payen12,13,14.
Abstract
INTRODUCTION: Septic shock is one of the most frequent causes of admission to the intensive care unit (ICU) and is associated with a poor prognosis. Early and late death in septic shock should be distinguished because they may involve different underlying mechanisms. In various conditions, the neutrophil-to-lymphocyte count ratio (NLCR) has been described as an easily measurable parameter to express injury severity. In the present study, we investigated whether the timing of death was related to a particular NLCR.Entities:
Mesh:
Year: 2015 PMID: 26671018 PMCID: PMC4699332 DOI: 10.1186/s13054-015-1144-x
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Patient characteristics
| All patients ( | Abdominal septic shock ( | Extra-abdominal septic shock ( |
| |
|---|---|---|---|---|
| Age, yr | 72.7 (60.3–82.4) | 72.5 (61.4–82) | 74 (58.7–84.2) | 0.76 |
| Female | 54 (41.5) | 42 (42.4) | 12 (38.7) | 0.54 |
| Male | 76 (58.5) | 57 (57.6) | 19 (61.3) | 0.54 |
| Origin of sepsis | ||||
| Digestive tract | 99 (74.6) | 99 (100) | 0 (0) | |
| Bone and soft tissue | 14 (11) | 0 (0) | 14 (45) | |
| Pulmonary | 7 (5) | 0 (0) | 7 (22) | |
| Urinary tract | 6 (4) | 0 (0) | 6 (19) | |
| Blood/endocarditis | 4 (3) | 0 (0) | 4 (12) | |
| Comorbidities | ||||
| CAD | 24 (18) | 20 (20) | 4 (13) | 0.36 |
| Diabetes | 28 (21) | 23 (23) | 5 (16) | 0.4 |
| COPD | 13 (10) | 8 (8) | 5 (16) | 0.19 |
| Cancer/immunosuppression | 33 (25) | 28 (28) | 5 (16) | 0.17 |
| Charlson comorbidity index score | 5 (4–6) | 5 (4–6) | 5 (4–6) | 0.86 |
| Severity and outcome | ||||
| SAPS II | 52.5 (42–60.8) | 52 (40.5–61) | 53 (44–59) | 0.61 |
| SOFA score at admission | 8 (6–12) | 8 (6–11.5) | 9 (8–12) | 0.066 |
| In-ICU LOS | 5 (2–11.8) | 5 (2–10) | 10 (3–18) | 0.061 |
| In-ICU mortality | 54 (41.5) | 37 (37.4) | 17 (54.8) | 0.085 |
| Hospital-acquired infection | 29 (22.3) | 20 (20.2) | 9 (29) | 0.3 |
| Cell counts at admission | ||||
| Neutrophils, 109/L | 9.7 (4–16.3) | 10.1 (3.9–16.3) | 8.3 (5.8–17.1) | 0.78 |
| Lymphocytes, 109/L | 0.8 (0.5–1.3) | 0.8 (0.5–1.3) | 0.9 (0.6–1.4) | 0.88 |
| NLCR | 9.3 (4.8–18.2) | 9 (4.6–17.9) | 11.5 (5.5–18.5) | 0.47 |
Abbreviations: CAD coronary artery disease, COPD chronic obstructive pulmonary disease, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, LOS length of stay, NLCR neutrophil-to-lymphocyte count ratio
Continuous variables are expressed as median with interquartile range or count with percentage, as appropriate
Fig. 1Flowchart depicting the study process. ICU intensive care unit
Patient characteristics according to survivors and nonsurvivors
| All patients | |||
|---|---|---|---|
| Survivors ( | Nonsurvivors ( |
| |
| Age, yr | 70.7 (57.9–81.7) | 75.7 (64.6–83.3) | 0.095 |
| Female | 31 (40.8) | 23 (42.6) | 0.84 |
| Male | 45 (59.2) | 31 (57.4) | |
| Comorbidities | |||
| CAD | 14 (18.4) | 10 (18.5) | 0.99 |
| Diabetes | 16 (21.1) | 12 (22.2) | 0.87 |
| COPD | 8 (10.5) | 5 (9.3) | 0.81 |
| Cancer/immunosuppression | 19 (25) | 14 (25.9) | 0.9 |
| Charlson comorbidity index score | 5 (3–6) | 5 (4–6.8) | 0.052 |
| Severity and outcome | |||
| SAPS II | 44 (39.8–54) | 59.5 (53–70) | <0.0001 |
| SOFA score at admission | 7 (5.8–9) | 12 (7–14.8) | <0.0001 |
| In-ICU LOS | 7 (4–11.2) | 3 (1.2–11.8) | 0.0049 |
| Hospital-acquired infection | 12 (15.8) | 17 (31.5) | 0.034 |
| Cell counts at admission | |||
| Neutrophils, 109/L | 9.7 (5.5–16.5) | 9.8 (3.2–16.2) | 0.43 |
| Lymphocytes, 109/L | 0.7 (0.5–1.1) | 1.1 (0.7–1.9) | 0.0022 |
| NLCR | 12.5 (6.5–21.2) | 6.2 (3.7–12.6) | 0.0014 |
Abbreviations: CAD coronary artery disease, COPD chronic obstructive pulmonary disease, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, LOS length of stay, NLCR neutrophil-to-lymphocyte count ratio
Continuous variables are expressed as median with interquartile range or count with percentage, as appropriate
Patient characteristics according to survivors, early death, and late death
| Survivors ( | Early death ( | Late death ( |
|
| |
|---|---|---|---|---|---|
| Age, yr | 70.7 (57.9–81.7) | 74.7 (65–81.9) | 77.9 (64.4–85.7) | 0.57 | 0.38 |
| Female | 31 (40.8) | 14 (42.4) | 9 (42.9) | 0.9 | 0.97 |
| Male | 45 (59.2) | 19 (57.6) | 12 (57.1) | 0.97 | |
| Comorbidities | |||||
| CAD | 14 (18.4) | 7 (21.2) | 3 (14.3) | 0.64 | 0.51 |
| Diabetes | 16 (21.1) | 5 (15.2) | 7 (33.3) | 0.30 | 0.12 |
| COPD | 8 (10.5) | 3 (9.1) | 2 (9.5) | 0.84 | 0.96 |
| Cancer/immunosuppression | 19 (25) | 8 (24.2) | 6 (28.6) | 0.86 | 0.73 |
| Charlson comorbidity index score | 5 (3–6) | 5 (4–6) | 5 (4–7) | 0.15 | 0.97 |
| Severity and outcome | |||||
| SAPS II | 44 (39.8–54) | 64 (56–76) | 55 (49–61) | <0.0001 | 0.003 |
| SOFA score at admission | 7 (5.8–9) | 13 (10–16) | 8 (6–9) | <0.0001 | 0.0004 |
| In-ICU LOS | 7 (4–11.2) | 2 (1–2) | 14 (10–22) | <0.0001 | <0.0001 |
| Hospital-acquired infection | 12 (15.8) | 3 (9.1) | 14 (66.7) | 0.035 | <0.0001 |
| Cell counts at admission | |||||
| Neutrophils, 109/L | 9.7 (5.5–16.5) | 6.9 (2.5–16.3) | 10.9 (6.1–13.2) | 0.15 | 0.25 |
| Lymphocytes, 109/L | 0.7 (0.5–1.1) | 0.9 (0.6–1.6) | 1.2 (0.9–2) | 0.35 | 0.17 |
| NLCR | 12.5 (6.5–21.2) | 5 (3.5–11.6) | 7 (4–12.9) | 0.011 | 0.41 |
Abbreviations: CAD coronary artery disease, COPD chronic obstructive pulmonary disease, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, LOS length of stay, NLCR neutrophil-to-lymphocyte count ratio
Continuous variables are expressed as median with interquartile range or count with percentage, as appropriate
Neutrophil, lymphocyte, and NLCR variations from admission to day 5 in late survivors and late nonsurvivors
| Survivors after day 5 ( | Late death after day 5 ( |
| |
|---|---|---|---|
| Age, yr | 72.5 (61.6–79.3) | 77.9 (64.4–85.7) | 0.2 |
| Female | 16 (32.7) | 9 (42.9) | 0.41 |
| Male | 33 (67.3) | 12 (57.1) | |
| Comorbidities | |||
| CAD | 12 (24.5) | 3 (14.3) | 0.34 |
| Diabetes | 11 (22.4) | 7 (33.3) | 0.34 |
| COPD | 7 (14.3) | 2 (9.5) | 0.59 |
| Cancer/immunosuppression | 10 (20.4) | 6 (28.6) | 0.46 |
| Charlson comorbidity index score | 5 (3–6) | 5 (4–7) | 0.66 |
| Severity and outcome | |||
| SAPS II | 48 (42–56) | 55 (49–61) | 0.083 |
| SOFA score at admission | 9 (6–10) | 8 (6–9) | 0.58 |
| In-ICU LOS | 10 (7–18) | 14 (10–22) | 0.15 |
| Hospital-acquired infection | 12 (24.5) | 14 (66.7) | 0.00082 |
| Cell counts at admission | |||
| Neutrophils, 109/L | 8.2 (5.5–16.1) | 10.9 (6.1–13.2) | 0.68 |
| Lymphocytes, 109/L | 0.7 (0.5–1.1) | 1.2 (0.9–2) | 0.0012 |
| NLCR | 11.8 (6.6–18.3) | 7 (4–12.9) | 0.06 |
| Cell counts at day 5 | |||
| Neutrophils, 109/L | 9.2 (6.7–11.8) | 16.4 (13.3–24.2) | 0.0001 |
| Lymphocytes, 109/L | 1 (0.8–1.3) | 1 (0.7–1.3) | 0.89 |
| NLCR | 9.1 (6.7–12.5) | 12.8 (8.4–35.4) | 0.028 |
| Cell counts variations from day 1 to day 5 | |||
| Neutrophils, % | 6.3 (−47.2 to 75.3) | 50.5 (3.4 to 207.0) | 0.026 |
| Lymphocytes, % | 33.3 (−20.0 to 141.7) | −21.8 (−43.2 to 44.6) | 0.034 |
| NLCR, % | −20.0 (−57.4 to 45.9) | 34.8 (−8.2 to 305.4) | 0.003 |
Abbreviations: CAD coronary artery disease, COPD chronic obstructive pulmonary disease, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, LOS length of stay, NLCR neutrophil-to-lymphocyte count ratio
Fig. 2Daily values of circulating neutrophils, lymphocytes, and neutrophil-to-lymphocyte count ratio (NLCR) from day 1 to day 5. Shaded bars represent nonsurvivors; open bars indicate survivors. p Values derived from two-way analysis of variance are reported in Additional file 1: Table S1. The box depict median value (thick bar) with 25the 75th, 10th and 90th percentiles
Fig. 3Receiver operating characteristic curves for the best neutrophil-to-lymphocyte count ratio (NLCR) thresholds to predict overall mortality (a), early death (b), and late death (c). Areas under the curve with 95 % confidence intervals are displayed in Additional file 2: Table S2